CUSIP 578784100 · who reports it, how much, and how much it matters to them
29 of the 720 hedge fund managers we track reported shares of Maze Therapeutics, Inc. (Nasdaq: MAZE) on Form 13F for 30 June 2026. Between them they reported USD 405m. The largest position belongs to Deep Track Capital, at USD 111m. The manager with the most riding on it is Logos Global Management, where it is 2.5% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Deep Track Capital1 fund on PPLI.com | USD 111m | 1.6% |
| 2 | Logos Global Management1 fund on PPLI.com | USD 58m | 2.5% |
| 3 | Braidwell12 funds on PPLI.com | USD 34m | 1.3% |
| 4 | Farallon Capital Management56 funds on PPLI.com | USD 33m | 0.2% |
| 5 | Marshall Wace LLP84 funds on PPLI.com | USD 27m | 0.0% |
| 6 | Citadel Advisors32 funds on PPLI.com | USD 25m | 0.0% |
| 7 | Casdin Capital3 funds on PPLI.com | USD 25m | 1.3% |
| 8 | Arrowmark Colorado Holdings24 funds on PPLI.com | USD 23m | 1.0% |
| 9 | Sphera Funds Management1 fund on PPLI.com | USD 12m | 1.6% |
| 10 | Hudson Bay Capital Management8 funds on PPLI.com | USD 8.1m | 0.0% |
| 11 | Adage Capital Management1 fund on PPLI.com | USD 7.4m | 0.0% |
| 12 | RTW Investments2 funds on PPLI.com | USD 6.3m | 0.1% |
| 13 | Two Sigma Investments35 funds on PPLI.com | USD 5.8m | 0.0% |
| 14 | Boothbay Fund Management2 funds on PPLI.com | USD 5.6m | 0.1% |
| 15 | Exoduspoint Capital Management7 funds on PPLI.com | USD 5.5m | 0.0% |
| 16 | HighVista Strategies27 funds on PPLI.com | USD 4.1m | 0.9% |
| 17 | Walleye Capital8 funds on PPLI.com | USD 3.8m | 0.0% |
| 18 | Exome Asset Management2 funds on PPLI.com | USD 3.4m | 2.1% |
| 19 | Dafna Capital Management6 funds on PPLI.com | USD 1.9m | 0.4% |
| 20 | Balyasny Asset Management25 funds on PPLI.com | USD 602,000 | 0.0% |
| 21 | Squarepoint Ops7 funds on PPLI.com | USD 580,000 | 0.0% |
| 22 | Verition Fund Management3 funds on PPLI.com | USD 543,000 | 0.0% |
| 23 | Verdad Advisers6 funds on PPLI.com | USD 377,000 | 0.4% |
| 24 | Jain Global1 fund on PPLI.com | USD 365,000 | 0.0% |
| 25 | D. E. Shaw & Co.15 funds on PPLI.com | USD 359,000 | 0.0% |
| 26 | Engineers Gate Manager1 fund on PPLI.com | USD 333,000 | 0.0% |
| 27 | Entrypoint Capital1 fund on PPLI.com | USD 293,000 | 0.1% |
| 28 | Persistent Asset Partners10 funds on PPLI.com | USD 200,000 | 0.1% |
| 29 | The Quarry1 fund on PPLI.com | USD 4,924 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Logos Global Management | USD 58m | 2.5% |
| 2 | Exome Asset Management | USD 3.4m | 2.1% |
| 3 | Sphera Funds Management | USD 12m | 1.6% |
| 4 | Deep Track Capital | USD 111m | 1.6% |
| 5 | Casdin Capital | USD 25m | 1.3% |
| 6 | Braidwell | USD 34m | 1.3% |
| 7 | Arrowmark Colorado Holdings | USD 23m | 1.0% |
| 8 | HighVista Strategies | USD 4.1m | 0.9% |
| 9 | Dafna Capital Management | USD 1.9m | 0.4% |
| 10 | Verdad Advisers | USD 377,000 | 0.4% |
Maze Therapeutics, Inc. trades under the symbol MAZE on the Nasdaq. Its CUSIP, the code used on Form 13F, is 578784100.
29 of the 720 hedge fund managers PPLI.com tracks reported Maze Therapeutics, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Deep Track Capital (USD 111m), Logos Global Management (USD 58m), Braidwell (USD 34m), Farallon Capital Management (USD 33m) and Marshall Wace LLP (USD 27m).
29 managers in our coverage reported it, and between them they run 382 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Logos Global Management, where the position was 2.5% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Maze Therapeutics, Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.